Literature DB >> 29449687

Reproductive endocrinology: Postmenopausal hormone therapy to prevent chronic conditions.

Susan D Reed1.   

Abstract

Mesh：

Year:  2018        PMID： 29449687     DOI： 10.1038/nrendo.2018.11

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale.

Authors: 
Journal:  Ann Intern Med       Date:  2002-11-19       Impact factor: 25.391

2.  Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2013-01-01       Impact factor: 25.391

3.  Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial.

Authors:  Rowan T Chlebowski; Wendy Barrington; Aaron K Aragaki; JoAnn E Manson; Gloria Sarto; Mary J OʼSullivan; Daniel Wu; Jane A Cauley; Lihong Qi; Robert L Wallace; Ross L Prentice
Journal:  Menopause       Date:  2017-02       Impact factor: 2.953

4.  Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: US Preventive Services Task Force Recommendation Statement.

Authors:  David C Grossman; Susan J Curry; Douglas K Owens; Michael J Barry; Karina W Davidson; Chyke A Doubeni; John W Epling; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Carol M Mangione; Maureen G Phipps; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng
Journal:  JAMA       Date:  2017-12-12       Impact factor: 56.272

5.  Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force.

Authors: 
Journal:  Ann Intern Med       Date:  2005-05-17       Impact factor: 25.391

6.  Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Authors:  Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller
Journal:  JAMA       Date:  2004-04-14       Impact factor: 56.272

7.  Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.

Authors:  James A Simon; François Laliberté; Mei Sheng Duh; Dominic Pilon; Kristijan H Kahler; Judit Nyirady; Pamela J Davis; Patrick Lefebvre
Journal:  Menopause       Date:  2016-06       Impact factor: 2.953

8.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.

Authors:  Sally A Shumaker; Claudine Legault; Lewis Kuller; Stephen R Rapp; Leon Thal; Dorothy S Lane; Howard Fillit; Marcia L Stefanick; Susan L Hendrix; Cora E Lewis; Kamal Masaki; Laura H Coker
Journal:  JAMA       Date:  2004-06-23       Impact factor: 56.272

10.  Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study.

Authors:  S Sweetland; V Beral; A Balkwill; B Liu; V S Benson; M Canonico; J Green; G K Reeves
Journal:  J Thromb Haemost       Date:  2012-11       Impact factor: 5.824
  10 in total
  1 in total

1.  Inhibiting Kiss1 Neurons With Kappa Opioid Receptor Agonists to Treat Polycystic Ovary Syndrome and Vasomotor Symptoms.

Authors:  Elizabeth A McCarthy; Daniel Dischino; Caroline Maguire; Silvia Leon; Rajae Talbi; Eugene Cheung; Claudio D Schteingart; Pierre J M Rivière; Susan D Reed; Robert A Steiner; Victor M Navarro
Journal:  J Clin Endocrinol Metab       Date:  2022-01-01       Impact factor: 6.134
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.